Arcutis Biotherapeutics grants director Robert Scott 2,819 restricted stock units
ARQT•Arcutis Biotherapeutics granted director Robert A. Scott 2,819 common shares on Oct. 23, 2026, along with two stock option awards covering 20,507 and 8,663 shares at a $31.20 exercise price each. Both options expire Oct. 23, 2036.
1. Equity awards
Arcutis Biotherapeutics granted director Robert A. Scott 2,819 common shares on Oct. 23, 2026. Scott also received stock options covering 20,507 shares and 8,663 shares, each with a $31.20 exercise price; both awards expire Oct. 23, 2036.
